iGMDRD134
Canonical SMILES: CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F
InChI: InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)
InChI Key: MLDQJTXFUGDVEO-UHFFFAOYSA-N
Drug Class:
Acids, HeterocyclicAntineoplastic AgentsAntineoplastic and Immunomodulating AgentsBCRP/ABCG2 InhibitorsBCRP/ABCG2 SubstratesBenzene DerivativesCytochrome P-450 CYP2C9 InhibitorsCytochrome P-450 CYP2C9 Inhibitors (weak)Cytochrome P-450 Enzyme InhibitorsEnzyme InhibitorsHeterocyclic CompoundsHeterocyclic Compounds, 1-RingHydrocarbonsHydrocarbons, AromaticHydrocarbons, CyclicImmunosuppressive AgentsKinase InhibitorMiscellaneous Therapeutic AgentsMyelosuppressive AgentsNicotinic AcidsP-glycoprotein/ABCB1 InhibitorsP-glycoprotein/ABCB1 SubstratesPotential QTc-Prolonging AgentsProtein Kinase InhibitorsPyridinesQTc Prolonging Agentsraf KinasesReceptors, Vascular Endothelial Growth FactorUGT1A1 InhibitorsUreaVascular Endothelial Growth Factor Receptor 2 AntagonistDrug Targets:
BRAF (P15056)RAF1 (P04049)VEGFRFLT4 (P35916)KDR (P35968)FLT3 (P36888)PDGFRB (P09619)KIT (P10721)FGFR1 (P11362)RET (P07949)FLT1 (P17948)Drug Pathways:
RTK signalingMAPK signaling pathwayErbB signaling pathwayVEGF signaling pathwayPathways in cancerRenal cell carcinomaThyroid cancerHepatocellular carcinomaDrug Synonyms:
Sorafenib (USAN/INN)Drug-model tissue-cancer distribution: Bubble Plot
Drug-gene pathway enrichments
Drug-gene GO enrichments
Drug-Gene: Aster Plot
Gene in drug-gene network: Network Plot

Models in Sorafenib
Loading, please wait...
Model | Level | Reference ID | Tissue | Cancer | Drug | Clinical Response | Source | |
---|---|---|---|---|---|---|---|---|
No matching records found |